Main therapeutic advances in IBD in 2007

In 2008 three biological agents against TNFalpha will be available. The combination of infliximab with azathioprine is no longer recommended, as hepatosplenic lymphomas with a particularly bad prognosis have been associated with this combined therapy. Regular maintenance therapy with infliximab is a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Revue médicale suisse 2008-01, Vol.4 (141), p.200, 202-200
Hauptverfasser:	Felley, Christian, Mottet, Christian, Maillard, Michel H, Hess, Jurg, Delarive, Joakim, Michetti, Pierre
Format:	Artikel
Sprache:	fre
Schlagworte:	Adalimumab Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Certolizumab Pegol Colitis, Ulcerative - drug therapy Crohn Disease - drug therapy Crohn Disease - surgery Humans Immunoglobulin Fab Fragments - therapeutic use Immunologic Factors - therapeutic use Infliximab Irritable Bowel Syndrome - drug therapy Polyethylene Glycols - therapeutic use Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In 2008 three biological agents against TNFalpha will be available. The combination of infliximab with azathioprine is no longer recommended, as hepatosplenic lymphomas with a particularly bad prognosis have been associated with this combined therapy. Regular maintenance therapy with infliximab is as effective in preventing the development of anti-infliximab antibodies as co-administration of this anti-TNFalpha agent with an immunomodulator. The benefit of regular maintenance therapy is probably linked to the presence of residual trough levels of infliximab between perfusions.
ISSN:	1660-9379